2026, Clinical Development, Pharmaceuticals and Small Molecule

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2026

Clinical Development

Pharmaceuticals

Small Molecule

AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development

The Pharma Data

DECEMBER 12, 2020

12, 2020– AstraZeneca and Alexion Pharmaceuticals, Inc. AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. 2 EvaluatePharma, World Preview 2020, Outlook to 2026.

Regulations

Regulations International Disease Small Molecule

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS. In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval.

Vaccine

Vaccine Therapies Trials Clinical Trials

Drug Discovery Digest

AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

Stay Connected